Rigel Pharma (RIGL) Reports In-Line Q1 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts RIGL Hot Sheet
Price: $50.55 +1.28%
EPS Growth %: -34.9%
Financial Fact:
Contract revenues from collaborations: 3.76M
Today's EPS Names:
SFBC, KSBI, PVBK, More
EPS Growth %: -34.9%
Financial Fact:
Contract revenues from collaborations: 3.76M
Today's EPS Names:
SFBC, KSBI, PVBK, More
Join SI Premium – FREE
Rigel Pharma (NASDAQ: RIGL) reported Q1 EPS of ($0.19), in-line with the analyst estimate of ($0.19). Revenue for the quarter came in at $5 million versus the consensus estimate of $4 million.
For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Orion Marine Group (ORN) Tops Q3 EPS by 3c ; Offers Guidance
- Christopher & Banks (CBK) Tops Q3 EPS by 79c
- Sound Finl Bancorp (SFBC) Tops Q3 EPS by 90c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
